We hypothesized that exosomal microRNAs could be implied in the pathogenesis of thromboembolic complications in coronavirus disease 2019 (COVID-19). We isolated …
Rationale In patients with COVID-19 pneumonia and mild hypoxaemia, the clinical benefit of high-flow nasal oxygen (HFNO) remains unclear. We aimed to examine whether HFNO …
A Roshdy, AS Elsayed… - Journal of Intensive Care …, 2023 - journals.sagepub.com
Objective: To explore the evidence surrounding the use of Airway Pressure Release Ventilation (APRV) in patients with coronavirus disease 2019 (COVID-19). Methods: A …
T Abe, T Takagi, T Fujii - Annual Update in Intensive Care and Emergency …, 2023 - Springer
Abstract The coronavirus disease 2019 (COVID-19) pandemic has been the biggest challenge to intensive care globally since the ventilator was invented to support patients with …
Z Ait Hamou, N Levy, J Charpentier, JP Mira… - Respiratory …, 2022 - Springer
Background High-flow nasal oxygen therapy (HFNC) may be an attractive first-line ventilatory support in COVID-19 patients. However, HNFC use for the management of …
M Schwarzinger, S Luchini, M Teschl, F Alla… - PLoS …, 2023 - journals.plos.org
Background Meta-analyses have shown that preexisting mental disorders may increase serious Coronavirus Disease 2019 (COVID-19) outcomes, especially mortality. However …
Background Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation …
A De Jong, A Bignon, F Stephan, T Godet… - The Lancet …, 2023 - thelancet.com
Background Non-invasive ventilation (NIV) and oxygen therapy (high-flow nasal oxygen [HFNO] or standard oxygen) following extubation have never been compared in critically ill …
H Chen, Y Zhan, J Zhang, S Cheng… - JMIR Public Health …, 2022 - publichealth.jmir.org
Background Nonalcoholic fatty liver disease (NAFLD) poses a substantial socioeconomic burden and is becoming the fastest growing driver of chronic liver disease, potentially …